Filtered By:
Drug: Investigational New Drugs

This page shows you your search results in order of date.

Order by Relevance | Date

Total 19 results found since Jan 2013.

Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes
This study aimed at investigating the influence of commercial transfection reagents (Prime-Fect, Leu-Fect A, and Leu-Fect C) complexed with different siRNAs (CDC20, HSP90, Mcl-1 and Survivin) in MDA-MB-436 breast cancer cells and the impact of incorporating an anionic additive, Trans-Booster, into siRNA formulations for improving in vitro gene silencing and delivery efficiency. Gene silencing was quantitatively analyzed by real-time RT-PCR while cell proliferation and siRNA uptake were evaluated by the MTT assay and flow cytometry, respectively. Amongst the investigated siRNAs and transfection reagents, Mcl-1/Prime-Fect co...
Source: Investigational New Drugs - July 14, 2022 Category: Drugs & Pharmacology Source Type: research

Abstracts of Presentations at the Association of Clinical Scientists 143 < sup > rd < /sup > Meeting Louisville, KY May 11-14,2022
Conclusion: These assays are suitable for routine diagnostic. The UltraFast NextGenPCR is the fastest with average time (30mins), followed by Agilent (2 hrs) and MassArray (6hrs). Upon completion of this activity, participants should be able to examine, measure and compare results from different assays for SARS detection, evaluate and diagnose accurately, as well as being able to plan, organize and recommend a diagnostic procedure for diagnostic laboratory. Key words: SARS-CoV-2, RNA extraction, RT-PCR, limit of detection, quantification cycle, COVID-19, in vitro diagnostic tests, Agilent, Massarray, Ultrafast. [20] From t...
Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Source Type: research

Investigation of the effects of the toll-like receptor 4 pathway on immune checkpoint vista in pancreatic cancer
In this study, we investigated the relation of TLR4 and downstream pathways with immune-check point VISTA in pancreatic cancer proliferation. We initially collected pancreatic cancer-related datasets using the GEPIA2 and UALCAN databases. Based on this data obtained the effect of various concentrations and incubation times of naloxone were used on PANC-1 cells proliferation. A combination of naloxone and VISTA-siRNA were applied, and the effect of both naloxone and combinedtreatment on TLR4, Interleukin 1 receptor associated kinase 4 (IRAK4) and VISTA gene expression were analyzed in pancreatic cancer cells. As a result of...
Source: Investigational New Drugs - February 3, 2022 Category: Drugs & Pharmacology Source Type: research

Temporary opening of the blood-brain barrier with the nitrone compound OKN-007
This study demonstrates that OKN-007 may be able to temporarily open up the BBB to augment the delivery of various compounds ranging in MW from as small as ~550 to as large as ~470 kDa. This compound is an investigational new drug for glioblastoma (GBM) therapy in clinical trials. The translational capability for human use to augment the delivery of non-BBB-permeable drugs is extremely high.PMID:34754607 | PMC:PMC8569329
Source: Molecular Medicine - November 10, 2021 Category: Molecular Biology Authors: Rheal A Towner Debra Saunders Megan Lerner Robert Silasi Mansat Tian Yuan Dylan Barber Janet Faakye Adam Nyul-Toth Anna Csiszar Beverley Greenwood-Van Meerveld Nataliya Smith Source Type: research

Development of a carrier system containing hyaluronic acid and protamine for siRNA delivery in the treatment of melanoma
SummaryThe use of small interfering RNA (siRNA) in melanoma treatment remains limited owing to its biological properties. Herein, we developed a carrier system containing hyaluronic acid and protamine for siRNA delivery. Considering zeta potential and particle size as standards, the ratio of each component in liposome nanoparticles prepared was screened using the control variable method, and siRNA cationic liposome nanoparticles were prepared based on the optimal results obtained. The encapsulation rate of the cationic liposome nanoparticles was measured, and particle morphology was observed. B16F10 cells were treated with...
Source: Investigational New Drugs - August 12, 2020 Category: Drugs & Pharmacology Source Type: research

New activators of eIF2 α Kinase Heme-Regulated Inhibitor (HRI) with improved biophysical properties.
New activators of eIF2α Kinase Heme-Regulated Inhibitor (HRI) with improved biophysical properties. Eur J Med Chem. 2019 Dec 16;187:111973 Authors: Zhang Q, Du R, Reis Monteiro Dos Santos GR, Yefidoff-Freedman R, Bohm A, Halperin J, Chorev M, Aktas BH Abstract Heme-regulated inhibitor (HRI), a eukaryotic translation initiation factor 2 alpha (eIF2α) kinase, is critically important for coupling protein synthesis to heme availability in reticulocytes and adaptation to various environmental stressors in all cells. HRI modifies the severity of several hemoglobin misfolding disorders including β-thalass...
Source: European Journal of Medicinal Chemistry - December 15, 2019 Category: Chemistry Authors: Zhang Q, Du R, Reis Monteiro Dos Santos GR, Yefidoff-Freedman R, Bohm A, Halperin J, Chorev M, Aktas BH Tags: Eur J Med Chem Source Type: research